About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 260 record(s)
Req # A-2020-001628
Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_02169963.Organization: Health Canada
November 2021
Req # A-2020-001633
Adverse Drug Reactions (ADRs) for INSULIN GLARGINE. Report numbers: 000914885, E2B_03177640, 000917355, E2B_03179056, E2B_03187375, E2B_03217648, E2B_03228735, E2B_03253131, E2B_03269421.Organization: Health Canada
November 2021
Req # A-2020-001643
Adverse Drug Reactions (ADRs) for METFORMIN HYDROCHLORIDE. Report numbers: 000913712, E2B_03197852, E2B_03266230, 000919396.Organization: Health Canada
November 2021
Req # A-2020-001690
Adverse Drug Reaction (ADR) for Mictoryl (propiverine hydrochloride). Report number: 000921739 ADR for Prevegyne (ascorbic acid). Report number: E2B_03314548 .Organization: Health Canada
November 2021
Req # A-2020-001752
Adverse Drug Reaction (ADR) for Botulinum toxin indication/injection site. Report number: E2B_03452307.Organization: Health Canada
November 2021
Req # A-2020-001939
Adverse Drug Reactions (ADRs) for Mezavant. Report numbers: E2B_03538381, E2B_03538386, E2B_03535705, E2B_03592302, E2B_03538369, E2B_03524778, E2B_03524679, E2B_03524716, E2B_03536534, E2B_03538403.Organization: Health Canada
November 2021
Req # A-2021-000022
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-101660-573.Organization: Health Canada
November 2021
Req # A-2021-000024
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-116088-925.Organization: Health Canada
November 2021
Req # A-2021-000037
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-100545-362.Organization: Health Canada
November 2021
Req # A-2021-000099
Adverse Drug Reactions (ADRs) for Varivax III. Report numbers: 000705268, 000706552, 000707195. ADRs for Zepatier. Report numbers: E2B_01496721, 000703672, 000704255, 000705883, 000706683. ADRs for Zostavax. Report numbers: E2B_01742359,…Organization: Health Canada
November 2021